Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose

Kondratieva, Alexandra; Palica, Katarzyna; Frøhlich, Christopher; Hovd, Rebekka Rolfsnes; Leiros, Hanna-Kirsti S.; Erdelyi, Mate; Bayer, Annette

doi:10.1016/j.ejmech.2024.116140

European Journal of Medicinal Chemistry

2024

DOI: 10.1016/j.ejmech.2024.116140

|View full text |Cite

Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose

Alexandra Kondratieva,

Katarzyna Palica,

Christopher Frøhlich

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors

Ortega-Balleza,

Vázquez-Jiménez,

Ortiz-Pérez

et al. 2024

Molecules

View full text Add to dashboard Cite

Currently, antimicrobial resistance (AMR) is a serious health problem in the world, mainly because of the rapid spread of multidrug-resistant (MDR) bacteria. These include bacteria that produce β-lactamases, which confer resistance to β-lactams, the antibiotics with the most prescriptions in the world. Carbapenems are particularly noteworthy because they are considered the ultimate therapeutic option for MDR bacteria. However, this group of antibiotics can also be hydrolyzed by β-lactamases, including metallo-β-lactamases (MBLs), which have one or two zinc ions (Zn2+) on the active site and are resistant to common inhibitors of serine β-lactamases, such as clavulanic acid, sulbactam, tazobactam, and avibactam. Therefore, the design of inhibitors against MBLs has been directed toward various compounds, with groups such as nitrogen, thiols, and metal-binding carboxylates, or compounds such as bicyclic boronates that mimic hydrolysis intermediates. Other compounds, such as dipicolinic acid and aspergillomarasmin A, have also been shown to inhibit MBLs by chelating Zn2+. In fact, recent inhibitors are based on Zn2+ chelation, which is an important factor in the mechanism of action of most MBL inhibitors. Therefore, in this review, we analyzed the current strategies for the design and mechanism of action of metal-ion-binding inhibitors that combat MDR bacteria.

show abstract

Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors

Ortega-Balleza,

Vázquez-Jiménez,

Ortiz-Pérez

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose

Cited by 1 publication

References 48 publications

Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors

Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors

Contact Info

Product

Resources

About